This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Express Scripts' Accredo & Akcea Tie Up to Distribute TEGSEDI
by Zacks Equity Research
Express Scripts (ESRX) likely to gain market traction through distribution of TEGSEDI.
Square-Merchant Relationship Deepens With New Payment Option
by Zacks Equity Research
Square (SQ) rolls out point-of-sale lending service called Square Installments that offers installment payment flexibility to the customers of its merchant clients.
Facebook Reportedly Testing Voice Commands on Messenger
by Zacks Equity Research
Facebook (FB) is working on a feature that will enable Messenger users to give voice commands to send messages, initiate voice calls and create reminders.
Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care
by Zacks Equity Research
Varian (VAR) enjoys solid presence in Asia, Latin America and Africa's cancer care space.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) likely to gain from focus on big-data based healthcare services.
Here's Why You Should Hold Medidata Stock in Your Portfolio
by Zacks Equity Research
Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.
SYNNEX Acquires Convergys to Create Growth Opportunities
by Zacks Equity Research
SYNNEX (SNX) to complete the acquisition of Convergys. It is likely to boost the company's leadership position in the customer relationship management, BPO space.
HP Provides Guidance for Fiscal 2019, Increases Dividend
by Zacks Equity Research
HP (HPQ) announces guidance for fiscal 2019 and hikes its planned quarterly dividend by 15%.
Synnex (SNX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Synnex (SNX) fiscal third-quarter results benefit from strong growth in technology solutions segment.
Here's Why You Should Hold Integer Holdings in Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.
Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up
by Zacks Equity Research
Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.
Tyler's Acquisition Spree Continues With MobileEyes Buyout
by Zacks Equity Research
Tyler Technologies (TYL) acquires MobileEyes to enhance its product portfolio with innovative technology solutions.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.
Baxter Collaborates With Mayo Clinic to Open Renal Care Center
by Zacks Equity Research
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Veeva's Technology Partner Joins Verix to Boost CRM Platform
by Zacks Equity Research
Veeva Systems' (VEEV) focus on cloud-based services is likely to favor the stock.
AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up
by Zacks Equity Research
AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.
New Strong Buy Stocks for September 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Cerner CommunityWorks Selected by Pershing Health System
by Zacks Equity Research
Cerner (CERN) witnesses consistent growth in the Electronic Health Record platform and Revenue Cycle Management solutions.
Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod
by Zacks Equity Research
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
Accuray's CyberKnife Manages Prostate Cancer Effectively
by Zacks Equity Research
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
Here's Why You Should Buy Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.
RTI Surgical's (RTIX) TETRAfuse Wins Spine Technology Award
by Zacks Equity Research
RTI Surgical (RTIX) to receive the Spine Technology Award from Orthopedics This Week at the NASS 33rd Annual Meeting in Los Angeles.
Boston Scientific Thrives in Urology on New LithoVue Empower
by Zacks Equity Research
Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.
Quest Diagnostics Grows in Fertility Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.
Abiomed's Impella Ensures Higher Survival Rates, Shares Up
by Zacks Equity Research
Abiomed's (ABMD) Impella successfully treats patients with cardiogenic shocks; market prospects bright.